NASD · Healthcare · Biotechnology · USA
Cytokinetics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Cytokinetics discovers and develops small molecule drugs that modulate muscle function for treating cardiovascular and neuromuscular diseases. The company's first approved product is MYQORZO, a cardiac myosin inhibitor authorized by the FDA, European Commission, and China for treating obstructive hypertrophic cardiomyopathy. The company maintains a pipeline of investigational candidates in various development stages.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Cytokinetics Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: not even its current assets cover what it owes.
17 more funds hold it; the full list is part of the paid plan.
137 more in this industry show a wider margin of safety.
We do not publish a verdict on CYTK yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-20 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.